Stockreport

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]

Edgewise Therapeutics, Inc.  (EWTX) 
PDF – Positive interim topline data for DUNE trial of sevasemten in Becker – – Expanded Phase 2 LYNX trial of sevasemten in Duchenne – – Anticipated to overenroll Phase [Read more]